MIDLOTHIAN, Va., May 7, 2020 /PRNewswire/ -- This week, the first patients are enrolling in two phase 2 clinical trials for COVID-19 using Pulmotect's PUL-042, an inhaled immunomodulatory agent to ...
NESS ZIONA, Israel--(BUSINESS WIRE)--Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, reports that the Israeli Patent Office (ILPO) ...
NESS ZIONA, Israel--(BUSINESS WIRE)-- Kamada, a bio-pharmaceutical company engaged in the development, manufacturing and marketing of specialty life-saving therapeutics, announced today that it ...
SAN DIEGO, Sept. 26, 2011 /PRNewswire/ -- Elevation Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of new aerosol therapies for patients with respiratory diseases, ...
AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced molgramostim has been awarded an Innovation ...
ARIKAYCE is delivered by a novel inhalation device, the Lamira® Nebulizer System, developed by PARI. Lamira® is a quiet, portable nebulizer that enables efficient aerosolization of ARIKAYCE via a ...
To be effective in treating respiratory illnesses, liquid drugs must be utilized in an aerosol with an effective and defined drop size distribution for inhaled medications. To meet these intense ...
Insmed Announces CLEAR-108 Phase 3 Clinical Study of ARIKACE® in Cystic Fibrosis Patients with Pseudomonas Lung Infections Has Completed Target Enrollment MONMOUTH JUNCTION, N.J., Nov. 13, 2012 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback